Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

NCT: NCT06366217 · COMPLETED

NCT IDNCT06366217
StatusCOMPLETED
Start Date2024-10-01
Completion2025-07-07
SponsorUniversity of California, San Francisco (OTHER)
First posted
Last updated

Brief Summary

To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.

Frequently Asked Questions

What is Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients?

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients is a clinical trial registered under NCT06366217. Current status: COMPLETED.

What is the status of NCT06366217?

The current status of NCT06366217 (Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients) is: COMPLETED.

When did Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients start?

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients started on 2024-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.